Impilo-backed Scantox completed the acquisition of Gentronix.

Impilo-backed Scantox, a preclinical GLP-accredited CRO, completed the acquisition of Gentronix, a GLP compliant genetic toxicology contract research rrganization. Financial terms were not disclosed. “Becoming a part of Scantox Group is a fantastic next step for Gentronix, opening up unique possibilities for us to offer an even greater service portfolio to our clients. As an organization we look forward to collaborating with our new colleagues and continuing to support the delivery of world-leading contract research services to our customers. There is a strong strategic rationale in teaming up with Scantox and we have identified multiple commercial synergies," Matt Tate, Gentronix CEO.